Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) - Association for Glycogen Storage Disease

Back to News and Articles

Donate to AGSD

Thank you for your support!

Become a Member

Access to scholarships, events, and more!

Published On: August 20, 2026

dtx401-fall-update

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

DTX401 program updates and global community engagement highlights.

View Community Update